Advertisement

Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium

Published:November 14, 2022DOI:https://doi.org/10.1016/j.jtho.2022.10.020

      Abstract

      Introduction

      We explored the association of respiratory and cardiometabolic comorbidities with NSCLC overall survival (OS) and lung cancer-specific survival (LCSS), by stage, in a large, multicontinent NSCLC pooled data set.

      Methods

      On the basis of patients pooled from 11 International Lung Cancer Consortium studies with available respiratory and cardiometabolic comorbidity data, adjusted hazard ratios (aHRs) were estimated using Cox models for OS. LCSS was evaluated using competing risk Grey and Fine models and cumulative incidence functions. Logistic regression (adjusted OR [aOR]) was applied to assess factors associated with surgical resection.

      Results

      OS analyses used patients with NSCLC with respiratory health or cardiometabolic health data (N = 16,354); a subset (n = 11,614) contributed to LCSS analyses. In stages I to IIIA NSCLC, patients with respiratory comorbidities had worse LCCS (stage IA aHR = 1.51, confidence interval [CI]: 1.17–1.95; stages IB–IIIA aHR = 1.20, CI: 1.06–1.036). In contrast, patients with stages I to IIIA NSCLC with cardiometabolic comorbidities had a higher risk of death from competing (non-NSCLC) causes (stage IA aHR = 1.34, CI: 1.12–1.69). The presence of respiratory comorbidities was inversely associated with having surgical resection (stage IA aOR = 0.54, CI: 0.35–0.83; stages IB–IIIA aOR = 0.57, CI: 0.46–0.70).

      Conclusions

      The presence of either cardiometabolic or respiratory comorbidities is associated with worse OS in stages I to III NSCLC. Patients with respiratory comorbidities were less likely to undergo surgery and had worse LCSS, whereas patients with cardiometabolic comorbidities had a higher risk of death from competing causes. As more treatment options for stages I to III NSCLC are introduced into the practice, accounting for cardiometabolic and respiratory comorbidities becomes essential in trial interpretation and clinical management.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Thoracic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sung H.
        • Ferlay J.
        • Siegel R.L.
        • et al.
        Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2021; 71: 209-249
        • Ramalingam S.S.
        • Vansteenkiste J.
        • Planchard D.
        • et al.
        Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC.
        N Engl J Med. 2020; 382: 41-50
        • Reck M.
        • Rodríguez-Abreu D.
        • Robinson A.G.
        • et al.
        Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater.
        J Clin Oncol. 2019; 37: 537-546
        • Peters S.
        • Camidge D.R.
        • Shaw A.T.
        • et al.
        Alectinib versus crizotinib in untreated ALK-positive non–small-cell lung cancer.
        N Engl J Med. 2017; 377: 829-838
        • Ward E.M.
        • Sherman R.L.
        • Henley S.J.
        • et al.
        Annual report to the nation on the status of cancer, featuring cancer in men and women age 20–49 years.
        J Natl Cancer Inst. 2019; 111: 1279-1297
        • Howlader N.
        • Forjaz G.
        • Mooradian M.J.
        • et al.
        The effect of advances in lung-cancer treatment on population mortality.
        N Engl J Med. 2020; 383: 640-649
        • Wu Y.L.
        • Tsuboi M.
        • He J.
        • et al.
        Osimertinib in resected EGFR-mutated non-small-cell lung cancer.
        N Engl J Med. 2020; 383: 1711-1723
        • Wakelee H.A.
        • Altorki N.K.
        • Zhou C.
        • et al.
        IMpower010: primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
        J Clin Oncol. 2021; 39 (8500–8500)
        • Forde P.M.
        • Spicer J.
        • Lu S.
        • et al.
        Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer.
        N Engl J Med. 2022; 386: 1973-1985
        • Grose D.
        • Morrison D.S.
        • Devereux G.
        • et al.
        Comorbidities in lung cancer: prevalence, severity and links with socioeconomic status and treatment.
        Postgrad Med J. 2014; 90: 305-310
        • Tammemagi C.M.
        • Neslund-Dudas C.
        • Simoff M.
        • Kvale P.
        Impact of comorbidity on lung cancer survival.
        Int J Cancer. 2003; 103: 792-802
        • Leduc C.
        • Antoni D.
        • Charloux A.
        • Falcoz P.E.
        • Quoix E.
        Comorbidities in the management of patients with lung cancer.
        Eur Respir J. 2017; 491601721
        • Birim O.
        • Kappetein A.P.
        • Bogers A.J.
        Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer.
        Eur J Cardiothorac Surg. 2005; 28: 759-762
        • Asmis T.R.
        • Ding K.
        • Seymour L.
        • et al.
        Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
        J Clin Oncol. 2008; 26: 54-59
        • Islam K.M.
        • Jiang X.
        • Anggondowati T.
        • Lin G.
        • Ganti A.K.
        Comorbidity and survival in lung cancer patients.
        Cancer Epidemiol Biomarkers Prev. 2015; 24: 1079-1085
        • Iachina M.
        • Jakobsen E.
        • Møller H.
        • et al.
        The effect of different comorbidities on survival of non-small cells lung cancer patients.
        Lung. 2015; 193: 291-297
        • Deleuran T.
        • Thomsen R.W.
        • Nørgaard M.
        • Jacobsen J.B.
        • Rasmussen T.R.
        • Søgaard M.
        Comorbidity and survival of Danish lung cancer patients from 2000–2011: a population-based cohort study.
        Clin Epidemiol. 2013; 5: 31-38
      1. The updated Charlson comorbidity index is a useful predictor of mortality in patients with Staphylococcus aureus bacteraemia | Epidemiology & infection. Cambridge Core. https://www.cambridge.org/core/journals/epidemiology-and-infection/article/updated-charlson-comorbidity-index-is-a-useful-predictor-of-mortality-in-patients-with-staphylococcus-aureus-bacteraemia/EB5C7C12D4FAACE25B38B1E7B9A79FEF. Accessed July 8, 2021.

        • Ganti A.K.
        • Siedlik E.
        • Marr A.S.
        • Loberiza Jr., F.R.
        • Kessinger A.
        Predictive ability of Charlson comorbidity index on outcomes from lung cancer.
        Am J Clin Oncol. 2011; 34: 593-596
        • Timmerman R.
        • Paulus R.
        • Galvin J.
        • et al.
        Stereotactic body radiation therapy for inoperable early stage lung cancer.
        JAMA. 2010; 303: 1070-1076
        • Carver J.R.
        • Shapiro C.L.
        • Ng A.
        • et al.
        American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.
        J Clin Oncol. 2007; 25: 3991-4008
        • Sekine Y.
        • Behnia M.
        • Fujisawa T.
        Impact of COPD on pulmonary complications and on long-term survival of patients undergoing surgery for NSCLC.
        Lung Cancer. 2002; 37: 95-101
        • Bobbio A.
        • Chetta A.
        • Ampollini L.
        • et al.
        Preoperative pulmonary rehabilitation in patients undergoing lung resection for non-small cell lung cancer.
        Eur J Cardiothorac Surg. 2008; 33: 95-98
        • Templeton R.
        • Greenhalgh D.
        Preoperative rehabilitation for thoracic surgery.
        Curr Opin Anaesthesiol. 2019; 32: 23-28
        • Daly M.E.
        Inoperable early-stage non–small-cell lung cancer: stereotactic ablative radiotherapy and rationale for systemic therapy.
        J Clin Oncol. 2022; 40: 539-545
        • Takenaka T.
        • Katsura M.
        • Shikada Y.
        • Tsukamoto S.
        • Takeo S.
        The impact of cardiovascular comorbidities on the outcome of surgery for non-small-cell lung cancer.
        Interact Cardiovasc Thorac Surg. 2013; 16: 270-274
        • Hardy D.
        • Liu C.C.
        • Cormier J.N.
        • Xia R.
        • Du X.L.
        Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer.
        Ann Oncol. 2010; 21: 1825-1833
        • Belzile-Dugas E.
        • Eisenberg M.J.
        Radiation-induced cardiovascular disease: review of an underrecognized pathology.
        J Am Heart Assoc. 2021; 10e021686
        • Wang K.
        • Eblan M.J.
        • Deal A.M.
        • et al.
        Cardiac toxicity after radiotherapy for stage III non–small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy.
        J Clin Oncol. 2017; 35: 1387-1394
        • Le Pechoux C.
        • Pourel N.
        • Barlesi F.
        • et al.
        Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3.
        Lancet Oncol. 2022; 23: 104-114